Merck & Co. signs $220M macrocyclic peptide deal after hailing ‘next wave of drug discovery’
Months after hailing macrocyclic peptides as the “next wave of drug discovery,” Merck & Co. | Months after hailing macrocyclic peptides as the “next wave of drug discovery,” Merck & Co. has pushed further into the space by penning a $220 million biobucks deal with Unnatural Products.
